NCT02236910 2024-10-15
Lu-DOTA-TATE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Unknown
Clinical Trials
12 trialsNCT05709171 2023-11-22
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Rigshospitalet, Denmark
Phase 2 Unknown
NCT02687958 2023-05-30
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Unknown
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04525638 2022-08-02
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Phase 2 Unknown
NCT05113355 2021-11-24
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02695459 2021-04-20
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
The Netherlands Cancer Institute
Phase 2 Unknown
NCT03279614 2017-09-12
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Peking University
Phase 2 Unknown
NCT03168607 2017-06-01
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Peking University
Phase 2 Unknown
NCT02409849 2015-04-07
Octreotide LAR as Maintenance Treatment for Patients With NEC
Peking University
Phase 2 Unknown
NCT00178698 2011-03-03
FR-WB-TT/che
The University of Texas Health Science Center, Houston
Phase 2 Unknown
NCT01203306 2010-09-16
XELBEVOCT
University of Turin, Italy
Phase 2 Unknown